Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Zolinza | vorinostat | Cutaneous T-cell lymphoma | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Zoryve | roflumilast | Plaque psoriasis | Reimburse with clinical criteria and/or conditions | Complete | ||
Zydelig | Idelalisib | Chronic lymphocytic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Zydelig | Idelalisib | Follicular Lymphoma | Do not reimburse | Complete | ||
Zykadia | Ceritinib | Metastatic Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
Zykadia (Resubmission) | Ceritinib | metastatic non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Zytiga | Abiraterone | Withdrawn | ||||
Zytiga | Abiraterone acetate | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn |